26
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

      research-article
      1 , 2 , 29 , 3 , 29 , 1 , 29 , 3 , 29 , 1 , 3 , 1 , 4 , 5 , 3 , 1 , 3 , 1 , 3 , 1 , 4 , 1 , 4 , 6 , 4 , 6 , 4 , 6 , 4 , 6 , 4 , 1 , 7 , 8 , 9 , 1 , 8 , 4 , 1 , 4 , 1 , 4 , 10 , 1 , 3 , 1 , 11 , 12 , 13 , 14 , 1 , 15 , 16 , 1 , 17 , 18 , 1 , 19 , 1 , 20 , 1 , 20 , 1 , 20 , 21 , 22 , 23 , 14 , 24 , 25 , 8 , The ISARIC4C Investigators 26 , the COVID-19 Genomics UK (COG-UK) consortium 27 , 1 , 24 , 3 , 28 , 3 , 4 , 1 , , 3 , 30 ,
      Cell
      Published by Elsevier Inc.
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S, and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild-type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the FDA, and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.

          Highlights

          • The receptor-binding motif (RBM) is a highly variable region of SARS-CoV-2 spike

          • RBM mutation N439K has emerged independently in multiple lineages

          • N439K increases spike affinity for hACE2; viral fitness and disease are unchanged

          • N439K confers resistance to several mAbs and escapes some polyclonal responses

          Abstract

          Epidemiological, clinical, molecular, and structural characterization of the N439K mutation in the SARS-CoV-2 spike receptor binding motif demonstrates that it results in similar viral fitness compared to wild-type, while conferring resistance against some neutralizing monoclonal antibodies and reducing the activity of some polyclonal antibody responses.

          Related collections

          Author and article information

          Journal
          Cell
          Cell
          Cell
          Published by Elsevier Inc.
          0092-8674
          1097-4172
          28 January 2021
          28 January 2021
          Affiliations
          [1 ]MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
          [2 ]Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
          [3 ]Vir Biotechnology, San Francisco, California 94158, USA
          [4 ]Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
          [5 ]Institute of Biodiversity, Animal Health and Comparative Medicine, Boyd Orr Centre for Population and Ecosystem Health, University of Glasgow, Glasgow, G61 1QH, UK
          [6 ]Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, EH9 3FL, UK
          [7 ]Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
          [8 ]Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
          [9 ]Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA
          [10 ]Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, CB2 0XY, UK
          [11 ]Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland
          [12 ]Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
          [13 ]Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland
          [14 ]Department of Chemistry and Hamilton Institute, Maynooth University, Maynooth, Ireland
          [15 ]Department of Nephrology, Ospedale Civico Lugano, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
          [16 ]Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, NSW 2052, Australia
          [17 ]Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland
          [18 ]ETH Institute of Microbiology, ETH Zurich, 8093 Zürich, Switzerland
          [19 ]Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland
          [20 ]III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy
          [21 ]NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7BE, UK
          [22 ]Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool L12 2AP, UK
          [23 ]National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK
          [24 ]The Roslin Institute, University of Edinburgh, Edinburgh, EH25 9RG, UK
          [25 ]Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, EH16 4SA, UK
          [28 ]Washington University School of Medicine, Saint Louis, Missouri 63110, USA
          Author notes
          []Corresponding author
          [26]

          ISARIC4C Investigators, see Consortia section

          [27]

          https://www.cogconsortium.uk, see Consortia section

          [29]

          These authors contributed equally

          [30]

          Lead Contact

          Article
          S0092-8674(21)00080-5
          10.1016/j.cell.2021.01.037
          7843029
          33621484
          0ac9d1af-70b6-4369-a75f-4f10a2d7dab5
          © 2021 Published by Elsevier Inc.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 30 October 2020
          : 12 December 2020
          : 22 January 2021
          Categories
          Article

          Cell biology
          Cell biology

          Comments

          Comment on this article